董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas E. Polen | 男 | Chairman, Chief Executive Officer and President | 53 | 1712.91万美元 | 52.76 | 2026-01-27 |
| Carrie L. Byington | 男 | Independent Director | 63 | 34.52万美元 | 0.55 | 2026-01-27 |
| Joanne Waldstreicher | 女 | Independent Director | 65 | 33.62万美元 | 0.23 | 2026-01-27 |
| Gregory J. Hayes | 男 | Independent Director | 65 | 22.35万美元 | 0.61 | 2026-01-27 |
| Robert L. Huffines | 男 | Independent Director | 60 | 未披露 | 0.02 | 2026-01-27 |
| Jacqueline Wright | 女 | Independent Director | 65 | 未披露 | 0.02 | 2026-01-27 |
| Timothy M. Ring | 男 | Independent Director | 68 | 33.52万美元 | 6.01 | 2026-01-27 |
| Claire M. Fraser | 女 | Independent Director | 71 | 34.47万美元 | 2.26 | 2026-01-27 |
| Christopher Jones | 男 | Independent Director | 71 | 36.52万美元 | 3.42 | 2026-01-27 |
| Bertram L. Scott | 男 | Independent Director | 75 | 37.52万美元 | 5.42 | 2026-01-27 |
| Jeffrey W. Henderson | 男 | Independent Director | 61 | 36.02万美元 | 0.80 | 2026-01-27 |
| R. Andrew Eckert | 男 | Independent Director | 65 | 36.52万美元 | 0.93 | 2026-01-27 |
| William M. Brown | 男 | Independent Director | 63 | 33.52万美元 | 0.35 | 2026-01-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas E. Polen | 男 | Chairman, Chief Executive Officer and President | 53 | 1712.91万美元 | 52.76 | 2026-01-27 |
| Roland Goette | 男 | Executive Vice President and President, EMEA | 64 | 未披露 | 未持股 | 2026-01-27 |
| Antoine Ezell | -- | Executive Vice President, President of the Americas and Chief Marketing Officer | 57 | 未披露 | 未持股 | 2026-01-27 |
| Richard Byrd | -- | Executive Vice President and President, Interventional Segment | 58 | 339.91万美元 | 8.31 | 2026-01-27 |
| Michael Garrison | -- | Executive Vice President and President, Medical Segment | 57 | 364.90万美元 | 8.76 | 2026-01-27 |
| Pavan Mocherla | -- | Executive Vice President and President, Greater Asia | 57 | 未披露 | 未持股 | 2026-01-27 |
| Shana Neal | -- | Executive Vice President and Chief People Officer | 60 | 330.83万美元 | 未持股 | 2026-01-27 |
| Michelle Quinn | -- | Executive Vice President and General Counsel | 58 | 未披露 | 未持股 | 2026-01-27 |
| David Shan | -- | Executive Vice President and Chief Integrated Supply Chain Officer | 56 | 未披露 | 未持股 | 2026-01-27 |
| Michael Feld | 女 | Executive Vice President and President, Life Sciences | 46 | 409.64万美元 | 0.41 | 2026-01-27 |
| Pamela L. Spikner | 女 | Senior Vice President, Chief Accounting Officer and Controller | 49 | 未披露 | 未持股 | 2026-01-27 |
| Vitor Roque | 男 | Interim Chief Financial Officer | 44 | 未披露 | 未持股 | 2026-01-27 |
董事简历
中英对照 | 中文 | 英文- Thomas E. Polen
-
Thomas E. Polen，他是Becton, Dickinson and Company（公开上市的医疗技术公司）的总裁、首席执行官兼董事会主席，自2021年4月起担任该职务。此前，他从2017年起担任BD总裁，直到2020年1月被任命为首席执行官。Polen先生于1999年在BD开始他的职业生涯，然后于2004年过渡到Baxter Healthcare，在那里他领导制药制造和服务业务，并担任战略营销副总裁。2007年，他被提升为百特注射药品业务总经理。自2009年重新加入BD以来，Polen先生曾担任多种领导职务，包括领导以120亿美元收购CareFusion和以240亿美元收购C.R. Bard, Inc.。
Thomas E. Polen,Chairman since April 2021; Chief Executive Officer since January 2020; President since April 2017; Chief Operating Officer from October 2018 to January 2020. - Thomas E. Polen，他是Becton, Dickinson and Company（公开上市的医疗技术公司）的总裁、首席执行官兼董事会主席，自2021年4月起担任该职务。此前，他从2017年起担任BD总裁，直到2020年1月被任命为首席执行官。Polen先生于1999年在BD开始他的职业生涯，然后于2004年过渡到Baxter Healthcare，在那里他领导制药制造和服务业务，并担任战略营销副总裁。2007年，他被提升为百特注射药品业务总经理。自2009年重新加入BD以来，Polen先生曾担任多种领导职务，包括领导以120亿美元收购CareFusion和以240亿美元收购C.R. Bard, Inc.。
- Thomas E. Polen,Chairman since April 2021; Chief Executive Officer since January 2020; President since April 2017; Chief Operating Officer from October 2018 to January 2020.
- Carrie L. Byington
-
Carrie L. Byington自2019年以来一直担任美国最大的公共学术医疗保健系统加州大学卫生学院的执行副校长。2017年至2019年，他担任德克萨斯A&M大学医学院院长、健康科学高级副总裁、德克萨斯A&M系统卫生服务副校长。1995年至2016年，他在犹他大学任教，担任多个领导职务，包括2015年至2016年担任犹他大学临床和转化科学中心主任和首席研究员。
Carrie L. Byington is the Executive Vice President of University of California Health, the largest public academic healthcare system in the United States, since 2019. He served as Dean of the College of Medicine, Senior Vice President for Health Sciences for Texas A&M University, and Vice Chancellor for Health Services for Texas A&M System from 2017 to 2019.From 1995 to 2016, served on the faculty of the University of Utah, serving in multiple leadership roles, including as Director and Principal Investigator, Center for Clinical and Translational Science at University of Utah Health from 2015 to 2016. - Carrie L. Byington自2019年以来一直担任美国最大的公共学术医疗保健系统加州大学卫生学院的执行副校长。2017年至2019年，他担任德克萨斯A&M大学医学院院长、健康科学高级副总裁、德克萨斯A&M系统卫生服务副校长。1995年至2016年，他在犹他大学任教，担任多个领导职务，包括2015年至2016年担任犹他大学临床和转化科学中心主任和首席研究员。
- Carrie L. Byington is the Executive Vice President of University of California Health, the largest public academic healthcare system in the United States, since 2019. He served as Dean of the College of Medicine, Senior Vice President for Health Sciences for Texas A&M University, and Vice Chancellor for Health Services for Texas A&M System from 2017 to 2019.From 1995 to 2016, served on the faculty of the University of Utah, serving in multiple leadership roles, including as Director and Principal Investigator, Center for Clinical and Translational Science at University of Utah Health from 2015 to 2016.
- Joanne Waldstreicher
-
Joanne Waldstreicher，她一直担任Structure Therapeutics公司的董事会成员（2022年12月以来）。自2012年12月起，Waldstreicher博士担任强生公司（NYSE： JNJ）的首席医疗官，自2002年起担任各种职务，包括强生Janssen Pharmaceutical Companies of Johnson & Johnson的亚太医学科学首席医疗官和主管（2011年至2012年），以及全球药物开发高级副总裁、主管（2007年至2009年）。在加入强生公司之前，Waldstreicher博士在默克研究实验室（Merck research Laboratories）负责内分泌学和代谢临床研究。Waldstreicher博士目前还担任纽约大学医学院（New York University School of Medicine）人口卫生系医学伦理部的附属教员。Waldstreicher博士在纽约城市大学布鲁克林学院获得化学学士学位，并在哈佛医学院获得医学博士学位。
Joanne Waldstreicher,has served as a member of Structure Therapeutics Inc. board of directors since December 2022. Since December 2012, Dr. Waldstreicher has served as Chief Medical Officer at Johnson & Johnson (NYSE: JNJ), where she has served in various roles since 2002, including Chief Medical Officer & Head, Asia Pacific Medical Science at Janssen Pharmaceutical Companies of Johnson & Johnson from 2011 to 2012 and Senior Vice President, Head, Global Drug Development from 2007 to 2009. Prior to joining Johnson & Johnson, Dr. Waldstreicher oversaw endocrinology and metabolism clinical research at Merck Research Laboratories. Dr. Waldstreicher also currently serves as a faculty affiliate of the Division of Medical Ethics, Department of Population Health at New York University School of Medicine. Dr. Waldstreicher received her B.A. in Chemistry at City University of New York, Brooklyn College, and her M.D. at Harvard Medical School. - Joanne Waldstreicher，她一直担任Structure Therapeutics公司的董事会成员（2022年12月以来）。自2012年12月起，Waldstreicher博士担任强生公司（NYSE： JNJ）的首席医疗官，自2002年起担任各种职务，包括强生Janssen Pharmaceutical Companies of Johnson & Johnson的亚太医学科学首席医疗官和主管（2011年至2012年），以及全球药物开发高级副总裁、主管（2007年至2009年）。在加入强生公司之前，Waldstreicher博士在默克研究实验室（Merck research Laboratories）负责内分泌学和代谢临床研究。Waldstreicher博士目前还担任纽约大学医学院（New York University School of Medicine）人口卫生系医学伦理部的附属教员。Waldstreicher博士在纽约城市大学布鲁克林学院获得化学学士学位，并在哈佛医学院获得医学博士学位。
- Joanne Waldstreicher,has served as a member of Structure Therapeutics Inc. board of directors since December 2022. Since December 2012, Dr. Waldstreicher has served as Chief Medical Officer at Johnson & Johnson (NYSE: JNJ), where she has served in various roles since 2002, including Chief Medical Officer & Head, Asia Pacific Medical Science at Janssen Pharmaceutical Companies of Johnson & Johnson from 2011 to 2012 and Senior Vice President, Head, Global Drug Development from 2007 to 2009. Prior to joining Johnson & Johnson, Dr. Waldstreicher oversaw endocrinology and metabolism clinical research at Merck Research Laboratories. Dr. Waldstreicher also currently serves as a faculty affiliate of the Division of Medical Ethics, Department of Population Health at New York University School of Medicine. Dr. Waldstreicher received her B.A. in Chemistry at City University of New York, Brooklyn College, and her M.D. at Harvard Medical School.
- Gregory J. Hayes
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Robert L. Huffines
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Jacqueline Wright
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Timothy M. Ring
-
Timothy M. Ring，他是Quest Diagnostics Incorporated首席独立董事。他于2017年退休，担任C. R. Bard, Inc.的董事长兼首席执行官，自2003年以来一直担任该职位。Ring先生是Becton, Dickinson And Company的董事，2003年至2017年担任C. R. Bard, Inc.的董事，2005年至2009年担任CIT Group Inc.的董事。他是TeamFund， Inc.的联合创始人，TeamFund， Inc.是一家影响力基金和非营利组织，专注于向Sub-Saharan Africa and India提供医疗技术。
Timothy M. Ring,is Lead Independent Director. He retired in 2017 as Chairman and Chief Executive Officer of C. R. Bard, Inc., positions in which he had served since 2003. Mr. Ring is a director of Becton, Dickinson and Company, and was director of C. R. Bard, Inc. from 2003 to 2017 and of CIT Group Inc. from 2005 to 2009. He is a co-founder of TeamFund, Inc., an impact fund and non-profit focused on delivering medical technology to Sub-Saharan Africa and India. - Timothy M. Ring，他是Quest Diagnostics Incorporated首席独立董事。他于2017年退休，担任C. R. Bard, Inc.的董事长兼首席执行官，自2003年以来一直担任该职位。Ring先生是Becton, Dickinson And Company的董事，2003年至2017年担任C. R. Bard, Inc.的董事，2005年至2009年担任CIT Group Inc.的董事。他是TeamFund， Inc.的联合创始人，TeamFund， Inc.是一家影响力基金和非营利组织，专注于向Sub-Saharan Africa and India提供医疗技术。
- Timothy M. Ring,is Lead Independent Director. He retired in 2017 as Chairman and Chief Executive Officer of C. R. Bard, Inc., positions in which he had served since 2003. Mr. Ring is a director of Becton, Dickinson and Company, and was director of C. R. Bard, Inc. from 2003 to 2017 and of CIT Group Inc. from 2005 to 2009. He is a co-founder of TeamFund, Inc., an impact fund and non-profit focused on delivering medical technology to Sub-Saharan Africa and India.
- Claire M. Fraser
-
Claire M. Fraser Liggett自2006年担任董事。自2007年她担任基因组科学协会董事，马里兰巴尔的摩的马里兰大学医学院教授。从1998年至2007年担任基因组研究协会的总裁和主管，该协会是非盈利的破译分析基因的中心。Dr. Fraser在美国科学院董事会工作。Dr. Fraser因其在传染病和分子诊断方面的著名科学家，脑阔新型诊断的发展和疫苗。
Claire M. Fraser Liggett is the Director of the Institute for Genome Sciences and a Professor of Medicine and Microbiology and Immunology at the University of Maryland School of Medicine since 2007. She served as President and Director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies, from 1998 to 2007.Chair of the Board and a Director of the American Association for the Advancement of Science.Previously served as a Director of Ohana Biosciences Inc. - Claire M. Fraser Liggett自2006年担任董事。自2007年她担任基因组科学协会董事，马里兰巴尔的摩的马里兰大学医学院教授。从1998年至2007年担任基因组研究协会的总裁和主管，该协会是非盈利的破译分析基因的中心。Dr. Fraser在美国科学院董事会工作。Dr. Fraser因其在传染病和分子诊断方面的著名科学家，脑阔新型诊断的发展和疫苗。
- Claire M. Fraser Liggett is the Director of the Institute for Genome Sciences and a Professor of Medicine and Microbiology and Immunology at the University of Maryland School of Medicine since 2007. She served as President and Director of The Institute for Genomic Research, a not-for-profit research organization engaged in human and microbial genomics studies, from 1998 to 2007.Chair of the Board and a Director of the American Association for the Advancement of Science.Previously served as a Director of Ohana Biosciences Inc.
- Christopher Jones
-
Christopher Jones自2010年担任董事。Mr. Jones在2001年在JWT Worldwide公司首席执行官 ，该公司是J. Walter Thompson，该公司是国际上市公司。自2002年Mr. Jones担任Motion Equity Partners （前身是 Cognetas 股份有限公司）的运营合伙人和董事，该公司泛欧洲私人抵押资产公司。他自2002年起担任Results国际集团公司非执行董事长。他还担任Pavilion Clinic董事会董事长，Johns Hopkins大学 Bloomberg公共健康学院健康顾问委员会成员。Mr. Jones 基于他成功的职业生涯，作为全球上市公司的领导者为国际前景做出了贡献。他为所在的领域提供了大量的上市、战略、管理专业设备。
Christopher Jones retired as Chief Executive Officer of JWT Worldwide (previously known as J. Walter Thompson), an international marketing firm, in 2001.He is the Chair of the Board of Trustees of The Pew Charitable Trusts and member of the Board of Directors of The Albert and Mary Lasker Foundation.Member of the Health Advisory Board of The Johns Hopkins University Bloomberg School of Public Health. - Christopher Jones自2010年担任董事。Mr. Jones在2001年在JWT Worldwide公司首席执行官 ，该公司是J. Walter Thompson，该公司是国际上市公司。自2002年Mr. Jones担任Motion Equity Partners （前身是 Cognetas 股份有限公司）的运营合伙人和董事，该公司泛欧洲私人抵押资产公司。他自2002年起担任Results国际集团公司非执行董事长。他还担任Pavilion Clinic董事会董事长，Johns Hopkins大学 Bloomberg公共健康学院健康顾问委员会成员。Mr. Jones 基于他成功的职业生涯，作为全球上市公司的领导者为国际前景做出了贡献。他为所在的领域提供了大量的上市、战略、管理专业设备。
- Christopher Jones retired as Chief Executive Officer of JWT Worldwide (previously known as J. Walter Thompson), an international marketing firm, in 2001.He is the Chair of the Board of Trustees of The Pew Charitable Trusts and member of the Board of Directors of The Albert and Mary Lasker Foundation.Member of the Health Advisory Board of The Johns Hopkins University Bloomberg School of Public Health.
- Bertram L. Scott
-
Bertram L. Scott，他是一名退休的医疗保健执行官，曾担任Affinity health Plan的总裁兼首席执行官（2012年至2014年）。在此之前，他从2010年到2011年担任CIGNA Corporation的美国商业总裁；2000年至2010年在TIAA-CREF担任多个行政领导职务，包括总裁兼首席执行官。他目前担任Equitable，Lowe's Companies,Inc.和碧迪医疗器械有限公司的董事会成员。
Bertram L. Scott,is a retired health care executive who formerly served as the President and Chief Executive Officer of Affinity Health Plan from 2012 to 2014. Prior to that, Mr. Scott served as the President, US Commercial at CIGNA Corporation from 2010 to 2011; and held multiple executive leadership roles at TIAA-CREF from 2000 to 2010, including President and Chief Executive Officer. Mr. Scott currently serves on the Board of Directors of Equitable, Lowe's Companies, Inc. and Becton, Dickinson and Company. - Bertram L. Scott，他是一名退休的医疗保健执行官，曾担任Affinity health Plan的总裁兼首席执行官（2012年至2014年）。在此之前，他从2010年到2011年担任CIGNA Corporation的美国商业总裁；2000年至2010年在TIAA-CREF担任多个行政领导职务，包括总裁兼首席执行官。他目前担任Equitable，Lowe's Companies,Inc.和碧迪医疗器械有限公司的董事会成员。
- Bertram L. Scott,is a retired health care executive who formerly served as the President and Chief Executive Officer of Affinity Health Plan from 2012 to 2014. Prior to that, Mr. Scott served as the President, US Commercial at CIGNA Corporation from 2010 to 2011; and held multiple executive leadership roles at TIAA-CREF from 2000 to 2010, including President and Chief Executive Officer. Mr. Scott currently serves on the Board of Directors of Equitable, Lowe's Companies, Inc. and Becton, Dickinson and Company.
- Jeffrey W. Henderson
-
Jeffrey W. Henderson自2015年9月起一直是Berkshire Partners LLC（一家私人股权投资公司）的咨询主任。2005年5月至2014年11月，他曾担任Cardinal Health Inc.（一家保健服务公司）的首席财务官。加盟Cardinal Health之前，Henderson先生在Eli Lilly公司和General Motors担任多个职位，包括担任Eli Lilly Canada的总裁兼总经理，Eli Lilly公司的主管和财务，并且在英国、新加坡、加拿大和美国的General Motors担任管理职位。自2015年8月起，Henderson先生一直担任Halozyme Therapeutics Inc.的董事；自2015年8月起，担任FibroGen, Inc.的董事。Henderson学生持有Kettering University电气工程的学士学位；Harvard Business School的工商管理硕士学位。
Jeffrey W. Henderson,has served as President of JWH Consulting LLC, an investment and business advisory firm, since January 2018. From 2015 to 2019, he served as a Healthcare Advisory Director to Berkshire Partners LLC. Mr. Henderson previously served as the Chief Financial Officer of Cardinal Health, Inc., a multinational health care services company, from May 2005 to November 2014, and in an executive capacity until his retirement from Cardinal in August 2015. From 1998 to 2005, Mr. Henderson held various senior management positions at Eli Lilly and Company, a multinational pharmaceutical company, including President and General Manager, Eli Lilly Canada, Inc. and Controller and Treasurer of Eli Lilly, Inc. He received his BS in electrical engineering from Kettering University, Flint, Mich., and his MBA from Harvard Graduate School of Business Administration. - Jeffrey W. Henderson自2015年9月起一直是Berkshire Partners LLC（一家私人股权投资公司）的咨询主任。2005年5月至2014年11月，他曾担任Cardinal Health Inc.（一家保健服务公司）的首席财务官。加盟Cardinal Health之前，Henderson先生在Eli Lilly公司和General Motors担任多个职位，包括担任Eli Lilly Canada的总裁兼总经理，Eli Lilly公司的主管和财务，并且在英国、新加坡、加拿大和美国的General Motors担任管理职位。自2015年8月起，Henderson先生一直担任Halozyme Therapeutics Inc.的董事；自2015年8月起，担任FibroGen, Inc.的董事。Henderson学生持有Kettering University电气工程的学士学位；Harvard Business School的工商管理硕士学位。
- Jeffrey W. Henderson,has served as President of JWH Consulting LLC, an investment and business advisory firm, since January 2018. From 2015 to 2019, he served as a Healthcare Advisory Director to Berkshire Partners LLC. Mr. Henderson previously served as the Chief Financial Officer of Cardinal Health, Inc., a multinational health care services company, from May 2005 to November 2014, and in an executive capacity until his retirement from Cardinal in August 2015. From 1998 to 2005, Mr. Henderson held various senior management positions at Eli Lilly and Company, a multinational pharmaceutical company, including President and General Manager, Eli Lilly Canada, Inc. and Controller and Treasurer of Eli Lilly, Inc. He received his BS in electrical engineering from Kettering University, Flint, Mich., and his MBA from Harvard Graduate School of Business Administration.
- R. Andrew Eckert
-
R. Andrew Eckert，于2016年9月被任命到碧迪医疗器械有限公司董事会。自2004年以来担任瓦里安医疗系统公司董事。自2011年1月起担任CRC保健公司（药物滥用治疗和青春期青少年服务的提供商）的的行政总裁。此前，从2009年10月到2011年1月，担任管理交响乐团科技集团（一家私募股权公司）的董事。从2005年10月至2009年5月担任Eclipsys公司（一个医疗信息管理软件供应商）的总裁兼行政总裁。从2004年到2005年担任SumTotal Systems公司（企业软件供应商）的行政总裁。从2002年到2004年担任Docent公司（被SumTotal Systems公司收购的一个企业软件供应商）的行政总裁。此前，1997年至2001年担任ADAC实验室（医疗影像公司）的董事长及行政总裁。在过去五年中曾担任Eclipsys公司的董事会。
R. Andrew Eckert currently serves as a Senior Advisor to Permira, a global private equity firm. He served as Chief Executive Officer of Zelis Inc., a provider of healthcare cost management and payments solutions, from 2020 to 2021.Served as President and Chief Executive Officer of Acelity L.P. Inc., a global wound care company, from 2017 until the sale of the company in October 2019.Served as the Chief Executive Officer of Valence Health, Inc., a healthcare information technology and services company, from 2015 until its sale in 2016.Previously served as Chief Executive Officer of TriZetto Corporation, a payer technology solutions firm, and Chief Executive Officer of CRC Health Group, a provider of specialized behavioral healthcare services.Also previously served as Chief Executive Officer of Eclipsys, a healthcare provider technology firm, and ADAC Laboratories, a medical capital equipment company. - R. Andrew Eckert，于2016年9月被任命到碧迪医疗器械有限公司董事会。自2004年以来担任瓦里安医疗系统公司董事。自2011年1月起担任CRC保健公司（药物滥用治疗和青春期青少年服务的提供商）的的行政总裁。此前，从2009年10月到2011年1月，担任管理交响乐团科技集团（一家私募股权公司）的董事。从2005年10月至2009年5月担任Eclipsys公司（一个医疗信息管理软件供应商）的总裁兼行政总裁。从2004年到2005年担任SumTotal Systems公司（企业软件供应商）的行政总裁。从2002年到2004年担任Docent公司（被SumTotal Systems公司收购的一个企业软件供应商）的行政总裁。此前，1997年至2001年担任ADAC实验室（医疗影像公司）的董事长及行政总裁。在过去五年中曾担任Eclipsys公司的董事会。
- R. Andrew Eckert currently serves as a Senior Advisor to Permira, a global private equity firm. He served as Chief Executive Officer of Zelis Inc., a provider of healthcare cost management and payments solutions, from 2020 to 2021.Served as President and Chief Executive Officer of Acelity L.P. Inc., a global wound care company, from 2017 until the sale of the company in October 2019.Served as the Chief Executive Officer of Valence Health, Inc., a healthcare information technology and services company, from 2015 until its sale in 2016.Previously served as Chief Executive Officer of TriZetto Corporation, a payer technology solutions firm, and Chief Executive Officer of CRC Health Group, a provider of specialized behavioral healthcare services.Also previously served as Chief Executive Officer of Eclipsys, a healthcare provider technology firm, and ADAC Laboratories, a medical capital equipment company.
- William M. Brown
-
William M. Brown自2024年5月1日起担任3M公司的首席执行官，自2025年3月1日起担任董事会主席。Brown先生是航空航天和国防技术解决方案的全球创新者L3Harris技术的前任董事会主席兼首席执行官，并于2021年6月至2022年6月担任该公司的执行主席。2019年6月至2021年6月担任董事长兼首席执行官。Brown先生此前曾担任Harris Corporation的董事长、总裁兼首席执行官，此前该公司于2019年与L-3通讯合并。他于2011年11月加入哈里斯公司，担任总裁兼首席执行官，并于2014年4月被任命为董事长。在哈里斯公司之前，布朗先生在联合技术公司工作了14年，担任过各种领导职务。
William M. Brown,Brown has been the Chief Executive Officer of 3M Company since May 1, 2024, and Chairman of the Board since March 1, 2025.Mr. Brown is the former Chairman of the Board and Chief Executive Officer of L3Harris Technologies, a global innovator in aerospace and defense technology solutions, where he served as Executive Chair from June 2021 to June 2022. He served as Chairman and Chief Executive Officer from June 2019 to June 2021.Mr. Brown previously served as Chairman, President and Chief Executive Officer of Harris Corporation, prior to its merger with L3 Technologies in 2019. He joined Harris Corporation in November 2011 as President and Chief Executive Officer and was appointed Chairman in April 2014.Prior to Harris Corporation, Mr. Brown spent 14 years at United Technologies Corporation, serving in a variety of leadership roles. - William M. Brown自2024年5月1日起担任3M公司的首席执行官，自2025年3月1日起担任董事会主席。Brown先生是航空航天和国防技术解决方案的全球创新者L3Harris技术的前任董事会主席兼首席执行官，并于2021年6月至2022年6月担任该公司的执行主席。2019年6月至2021年6月担任董事长兼首席执行官。Brown先生此前曾担任Harris Corporation的董事长、总裁兼首席执行官，此前该公司于2019年与L-3通讯合并。他于2011年11月加入哈里斯公司，担任总裁兼首席执行官，并于2014年4月被任命为董事长。在哈里斯公司之前，布朗先生在联合技术公司工作了14年，担任过各种领导职务。
- William M. Brown,Brown has been the Chief Executive Officer of 3M Company since May 1, 2024, and Chairman of the Board since March 1, 2025.Mr. Brown is the former Chairman of the Board and Chief Executive Officer of L3Harris Technologies, a global innovator in aerospace and defense technology solutions, where he served as Executive Chair from June 2021 to June 2022. He served as Chairman and Chief Executive Officer from June 2019 to June 2021.Mr. Brown previously served as Chairman, President and Chief Executive Officer of Harris Corporation, prior to its merger with L3 Technologies in 2019. He joined Harris Corporation in November 2011 as President and Chief Executive Officer and was appointed Chairman in April 2014.Prior to Harris Corporation, Mr. Brown spent 14 years at United Technologies Corporation, serving in a variety of leadership roles.
高管简历
中英对照 | 中文 | 英文- Thomas E. Polen
Thomas E. Polen，他是Becton, Dickinson and Company（公开上市的医疗技术公司）的总裁、首席执行官兼董事会主席，自2021年4月起担任该职务。此前，他从2017年起担任BD总裁，直到2020年1月被任命为首席执行官。Polen先生于1999年在BD开始他的职业生涯，然后于2004年过渡到Baxter Healthcare，在那里他领导制药制造和服务业务，并担任战略营销副总裁。2007年，他被提升为百特注射药品业务总经理。自2009年重新加入BD以来，Polen先生曾担任多种领导职务，包括领导以120亿美元收购CareFusion和以240亿美元收购C.R. Bard, Inc.。
Thomas E. Polen,Chairman since April 2021; Chief Executive Officer since January 2020; President since April 2017; Chief Operating Officer from October 2018 to January 2020.- Thomas E. Polen，他是Becton, Dickinson and Company（公开上市的医疗技术公司）的总裁、首席执行官兼董事会主席，自2021年4月起担任该职务。此前，他从2017年起担任BD总裁，直到2020年1月被任命为首席执行官。Polen先生于1999年在BD开始他的职业生涯，然后于2004年过渡到Baxter Healthcare，在那里他领导制药制造和服务业务，并担任战略营销副总裁。2007年，他被提升为百特注射药品业务总经理。自2009年重新加入BD以来，Polen先生曾担任多种领导职务，包括领导以120亿美元收购CareFusion和以240亿美元收购C.R. Bard, Inc.。
- Thomas E. Polen,Chairman since April 2021; Chief Executive Officer since January 2020; President since April 2017; Chief Operating Officer from October 2018 to January 2020.
- Roland Goette
Roland Goette自2017年5月以来担任欧洲，中东和非洲地区执行副总裁兼总裁； 2014年10月至2017年5月担任欧洲总裁；在此之前，他是西欧医疗外科系统副总裁兼总经理。
Roland Goette,Executive Vice President and President, EMEA since May 2017.- Roland Goette自2017年5月以来担任欧洲，中东和非洲地区执行副总裁兼总裁； 2014年10月至2017年5月担任欧洲总裁；在此之前，他是西欧医疗外科系统副总裁兼总经理。
- Roland Goette,Executive Vice President and President, EMEA since May 2017.
- Antoine Ezell
Antoine Ezell，自2020年10月起担任北美区总裁；自2020年1月起担任执行副总裁兼首席营销官；2019年1月至2020年1月，Eli Lilly公司负责连接护理和胰岛素的副总裁；在此之前，Eli Lilly公司负责企业能力和解决方案的副总裁；首席营销官，Elanco动物健康中心；Eli Lilly首席客户官。
Antoine Ezell,Executive Vice President, President of the Americas and Chief Marketing Officer since October 2020; Executive Vice President and Chief Marketing Officer from January 2020 to October 2020; Vice President, Connected Care and Insulins, Eli Lilly and Company from January 2019 to January 2020.- Antoine Ezell，自2020年10月起担任北美区总裁；自2020年1月起担任执行副总裁兼首席营销官；2019年1月至2020年1月，Eli Lilly公司负责连接护理和胰岛素的副总裁；在此之前，Eli Lilly公司负责企业能力和解决方案的副总裁；首席营销官，Elanco动物健康中心；Eli Lilly首席客户官。
- Antoine Ezell,Executive Vice President, President of the Americas and Chief Marketing Officer since October 2020; Executive Vice President and Chief Marketing Officer from January 2020 to October 2020; Vice President, Connected Care and Insulins, Eli Lilly and Company from January 2019 to January 2020.
- Richard Byrd
Richard Byrd，执行副总裁兼介入业务总裁，自2022年9月起至今；2019年3月至2022年9月担任BD给药解决方案全球总裁；2016年12月至2019年2月担任预分析系统全球总裁。
Richard Byrd,Executive Vice President and President, Interventional Segment since September 2022; Worldwide President, BD Medication Delivery Solutions from March 2019 to September 2022.- Richard Byrd，执行副总裁兼介入业务总裁，自2022年9月起至今；2019年3月至2022年9月担任BD给药解决方案全球总裁；2016年12月至2019年2月担任预分析系统全球总裁。
- Richard Byrd,Executive Vice President and President, Interventional Segment since September 2022; Worldwide President, BD Medication Delivery Solutions from March 2019 to September 2022.
- Michael Garrison
Michael Garrison，自2022年9月起担任医疗部门执行副总裁兼总裁；2020年3月至2022年9月担任BD药物管理解决方案全球总裁；2018年12月至2020年3月担任BD外科全球总裁；2016年7月至2018年12月担任副总裁兼全球输液系统总经理。
Michael Garrison,Executive Vice President and President, Medical Segment since September 2022; Worldwide President, BD Medication Management Solutions from March 2020 to September 2022; Worldwide President, BD Surgery from December 2018 to March 2020.- Michael Garrison，自2022年9月起担任医疗部门执行副总裁兼总裁；2020年3月至2022年9月担任BD药物管理解决方案全球总裁；2018年12月至2020年3月担任BD外科全球总裁；2016年7月至2018年12月担任副总裁兼全球输液系统总经理。
- Michael Garrison,Executive Vice President and President, Medical Segment since September 2022; Worldwide President, BD Medication Management Solutions from March 2020 to September 2022; Worldwide President, BD Surgery from December 2018 to March 2020.
- Pavan Mocherla
Pavan Mocherla，自2022年7月起担任执行副总裁兼大亚洲区总裁；2017年12月至2022年6月担任南亚地区总经理/董事总经理；2017年8月至2017年12月担任大亚洲区战略创新副总裁。
Pavan Mocherla,Executive Vice President and President, Greater Asia since July 2022; Country General Manager, South Asia/Managing Director from December 2017 to June 2022.- Pavan Mocherla，自2022年7月起担任执行副总裁兼大亚洲区总裁；2017年12月至2022年6月担任南亚地区总经理/董事总经理；2017年8月至2017年12月担任大亚洲区战略创新副总裁。
- Pavan Mocherla,Executive Vice President and President, Greater Asia since July 2022; Country General Manager, South Asia/Managing Director from December 2017 to June 2022.
- Shana Neal
Shana Neal，自2022年4月起担任执行副总裁兼首席人事官；自2018年4月至2022年3月担任Owens & Minor首席人力资源官；自2017年1月至2018年3月担任BD人力资源高级副总裁。
Shana Neal,Executive Vice President and Chief People Officer since April 2022; Chief Human Resources Officer of Owens & Minor from April 2018 to March 2022.- Shana Neal，自2022年4月起担任执行副总裁兼首席人事官；自2018年4月至2022年3月担任Owens & Minor首席人力资源官；自2017年1月至2018年3月担任BD人力资源高级副总裁。
- Shana Neal,Executive Vice President and Chief People Officer since April 2022; Chief Human Resources Officer of Owens & Minor from April 2018 to March 2022.
- Michelle Quinn
Michelle Quinn，自2013年4月起担任执行副总裁兼总法律顾问；从2022年2月到2023年4月，担任高级副总裁、副总法律顾问兼首席道德与合规官；2019年5月至2023年1月，高级副总裁、首席道德与合规官、首席监管顾问；2019年2月至2019年5月担任高级副总裁兼首席合规官；2017年1月至2019年1月，Sandoz Inc.担任北美副总裁兼总法律顾问。
Michelle Quinn,Executive Vice President and General Counsel since April 2023; Senior Vice President, Deputy General Counsel and Chief Ethics and Compliance Officer from February 2022 to April 2023; Senior Vice President, Chief Ethics & Compliance Officer, Chief Regulatory Counsel from May 2019 to January 2023; Senior Vice President, Chief Compliance Officer from February 2019 to May 2019.- Michelle Quinn，自2013年4月起担任执行副总裁兼总法律顾问；从2022年2月到2023年4月，担任高级副总裁、副总法律顾问兼首席道德与合规官；2019年5月至2023年1月，高级副总裁、首席道德与合规官、首席监管顾问；2019年2月至2019年5月担任高级副总裁兼首席合规官；2017年1月至2019年1月，Sandoz Inc.担任北美副总裁兼总法律顾问。
- Michelle Quinn,Executive Vice President and General Counsel since April 2023; Senior Vice President, Deputy General Counsel and Chief Ethics and Compliance Officer from February 2022 to April 2023; Senior Vice President, Chief Ethics & Compliance Officer, Chief Regulatory Counsel from May 2019 to January 2023; Senior Vice President, Chief Compliance Officer from February 2019 to May 2019.
- David Shan
David Shan，自2023年1月起担任执行副总裁兼首席集成供应链官；从2020年3月到2023年8月担任执行副总裁兼首席质量官；2018年5月至2020年8月担任全球供应链高级副总裁；2017年12月至2018年5月担任全球运营设备高级副总裁。
David Shan,Executive Vice President and Chief Integrated Supply Chain Officer since January 2023; Executive Vice President and Chief Quality Officer from March 2020 to August 2023; Senior Vice President, Global Supply Chain from May 2018 to August 2020.- David Shan，自2023年1月起担任执行副总裁兼首席集成供应链官；从2020年3月到2023年8月担任执行副总裁兼首席质量官；2018年5月至2020年8月担任全球供应链高级副总裁；2017年12月至2018年5月担任全球运营设备高级副总裁。
- David Shan,Executive Vice President and Chief Integrated Supply Chain Officer since January 2023; Executive Vice President and Chief Quality Officer from March 2020 to August 2023; Senior Vice President, Global Supply Chain from May 2018 to August 2020.
- Michael Feld
Michael Feld，自2024年8月起担任生命科学执行副总裁兼总裁；从2023年9月到2024年8月担任Hach （Veralto Corporation）总裁；从2022年6月到2023年9月担任Danaher Corporation的高级副总裁兼总经理；从2019年1月到2022年9月，担任Mammotome （Danaher Corporation）的总裁。
Michael Feld,Executive Vice President and President, Life Sciences since August 2024; President of Hach (Veralto Corporation) from September 2023 to August 2024; Senior Vice President and General Manager of Danaher Corporation from June 2022 to September 2023; and President of Mammotome (Danaher Corporation) from January 2019 to September 2022.- Michael Feld，自2024年8月起担任生命科学执行副总裁兼总裁；从2023年9月到2024年8月担任Hach （Veralto Corporation）总裁；从2022年6月到2023年9月担任Danaher Corporation的高级副总裁兼总经理；从2019年1月到2022年9月，担任Mammotome （Danaher Corporation）的总裁。
- Michael Feld,Executive Vice President and President, Life Sciences since August 2024; President of Hach (Veralto Corporation) from September 2023 to August 2024; Senior Vice President and General Manager of Danaher Corporation from June 2022 to September 2023; and President of Mammotome (Danaher Corporation) from January 2019 to September 2022.
- Pamela L. Spikner
Pamela L. Spikner，自2021年7月起担任R1 RCM首席会计官。Spikner女士此前还曾于2019年7月至2021年7月担任医疗技术提供商Hill-Rom Holdings, Inc.的助理公司控制人。Spikner女士于2007年9月至2019年7月在公用事业服务控股公司艾索伦电力公司担任过各种会计领导职务。
Pamela L. Spikner,served as Chief Accounting Officer of R1 RCM since July 2021. Ms. Spikner also previously was Assistant Corporate Controller of Hill-Rom Holdings, Inc., a medical technology provider, from July 2019 to July 2021. Ms. Spikner held various accounting leadership roles at Exelon Corporation, a utility services holding company, from September 2007 to July 2019.- Pamela L. Spikner，自2021年7月起担任R1 RCM首席会计官。Spikner女士此前还曾于2019年7月至2021年7月担任医疗技术提供商Hill-Rom Holdings, Inc.的助理公司控制人。Spikner女士于2007年9月至2019年7月在公用事业服务控股公司艾索伦电力公司担任过各种会计领导职务。
- Pamela L. Spikner,served as Chief Accounting Officer of R1 RCM since July 2021. Ms. Spikner also previously was Assistant Corporate Controller of Hill-Rom Holdings, Inc., a medical technology provider, from July 2019 to July 2021. Ms. Spikner held various accounting leadership roles at Exelon Corporation, a utility services holding company, from September 2007 to July 2019.
- Vitor Roque
Vitor Roque，自2024年9月起担任公司财务、业务部门和企业财务规划与分析高级副总裁。在此职位上，他监督所有业务部门的财务运营，并领导部门战略支持和财务规划和分析的核心能力。在担任现任职务之前，他在BD担任重要职务，包括2021年7月至2024年11月担任BD医疗部门的副总裁兼首席财务官，以及2019年1月至2021年8月担任药物管理解决方案财务副总裁。他拥有超过20年的全球金融和领导经验。
Vitor Roque,has served as the Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis at the Company since September 2024. In this role, he oversees the financial operations across all BD business units and leads the central capability for segment strategic support and financial planning and analysis. Prior to his current role, he held key positions at BD, including Vice President and CFO of BD Medical Segment from July 2021 through November 2024 and Vice President of Finance for Medication Management Solutions from January 2019 through August 2021. Mr. Roque hass more than 20 years of global finance and leadership experience.- Vitor Roque，自2024年9月起担任公司财务、业务部门和企业财务规划与分析高级副总裁。在此职位上，他监督所有业务部门的财务运营，并领导部门战略支持和财务规划和分析的核心能力。在担任现任职务之前，他在BD担任重要职务，包括2021年7月至2024年11月担任BD医疗部门的副总裁兼首席财务官，以及2019年1月至2021年8月担任药物管理解决方案财务副总裁。他拥有超过20年的全球金融和领导经验。
- Vitor Roque,has served as the Senior Vice President of Finance, Business Units and Corporate Financial Planning & Analysis at the Company since September 2024. In this role, he oversees the financial operations across all BD business units and leads the central capability for segment strategic support and financial planning and analysis. Prior to his current role, he held key positions at BD, including Vice President and CFO of BD Medical Segment from July 2021 through November 2024 and Vice President of Finance for Medication Management Solutions from January 2019 through August 2021. Mr. Roque hass more than 20 years of global finance and leadership experience.